AbbVie has disclosed that its late-stage monotherapy prospect substantially decreased the impact of the condition in patients as contrasted with placebo on the same day that various medications used in the treatment of Parkinson’s disorder are being questioned left, right, and center.
During the third phase of the TEMPO-1 experiment, two daily dosages of tavapadon, which is an oral dopamine receptor agonist, were evaluated. These doses were 5 mg and 15 mg. According to a statement, both arms significantly outperformed the placebo in terms of reducing disease burden at Week 26. This was determined by a composite score that included components of an industry assessment known as the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale.
According to the press announcement issued by AbbVie, tavapadon not only achieved the main target, but it also achieved a secondary endpoint, which related to the betterment of patients’ mobility in their day-to-day lives.
According to AbbVie, the majority of the negative reactions were mild to moderate in intensity and were consistent with the results of previous clinical studies.
A portion of tavapadon’s binding occurs at the D1 and D5 dopamine receptors, both of which are involved in the process of controlling motor activity. In addition to being explored as a monotherapy, it is also being tried in conjunction with levodopa, which is a biological counterpart to dopamine and is often used as an initial treatment for Parkinson’s disease.
According to the announcement issued by the pharmaceutical company, AbbVie intends to disclose the findings of a further phase 3 study of tavapadon later on in this year. This study is evaluating the drug’s efficacy as a monotherapy with a variable dosage.
Following the acquisition of Cerevel Therapeutics for an astounding $8.7 billion, the pharmaceutical company was able to acquire tavapadon the previous year. Additionally, emraclidine, which is now being studied for its effectiveness in treating psychosis associated with Alzheimer’s disease and schizophrenia, is the second high-performing drug of that agreement. The selective positive allosteric modulator of muscarinic M4 belongs to the same category as Karuna Therapeutics’ KarXT, which is now awaiting a decision from the FDA about its approval.
